Maia Biotech THIO Telomere Immunotherapy 2024

Maia Biotechnology presents its telomere-targeting immunotherapy platform, centered on lead candidate THIO (THIO-101) for hard-to-treat cancers including NSCLC, HCC, SCLC, and gliomas. The company outlines its dual mechanism of action approach, ongoing Phase 2 clinical trials, and clinical partnerships with Regeneron, targeting multiple FDA approvals for oncology indications with significant unmet medical need.